Cancer vaccine stops melanoma recurrence

A new personalized mRNA vaccine developed by Merck and Moderna has shown promising results in a phase 3 clinical trial for high-risk melanoma patients. The study demonstrated that the vaccine significantly reduced the risk of cancer recurrence and spread after surgery, marking the first positive phase 3 outcome for an mRNA-based cancer therapy. The vaccine targets tumor-specific neoantigens identified through genetic analysis to train the immune system to attack remaining cancer cells, aiming to extend survival for patients with advanced melanoma. Merck and Moderna plan to pursue regulatory approval and explore applications for other difficult-to-treat cancers.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل